Amneal (NASDAQ:AMRX) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectations

What happened

Amneal Pharmaceuticals reported Q3 2026 revenue of $862.7 million, up 10% from a year earlier and above analysts' estimates. Adjusted profit was $0.26 per share, also beating expectations, and the company raised its full-year revenue guidance to $3.2 billion at the midpoint.

Confirmed

Global impact / market context

Higher revenue and profit than analysts expected, plus a raised full-year outlook, suggest Amneal is selling more of its medicines than anticipated. That can support the share price because investors often pay more for a company when sales and earnings beat forecasts and management signals confidence.

Analyst inference

The company lifted its full-year revenue guidance to a $3.2 billion midpoint, 1.2% above analysts' consensus. However, free cash flow margin, which means the share of revenue left as cash after expenses and investments, fell to 7.7% from 13.5%, so investors may weigh profit growth against weaker cash generation.

Analyst inference

What to watch

1. Free cash flow margin fell to 7.7% from 13.5% a year earlier, so watch whether this cash measure recovers in coming quarters as revenue grows. Confirmed
2. Management raised full-year revenue guidance to $3.2 billion at the midpoint, so track whether actual sales land at or above that level through the rest of the year. Proposed
3. Adjusted EBITDA, a profit measure before certain costs, beat estimates with a 24% margin, so watch whether this stronger profitability holds as the company spends to support growth. Analyst inference

Evidence

• stockstory.org